Press release
Advanced Cervical Cancer Pipeline Appears Robust With 70+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
Advanced Cervical Cancer Pipeline
Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Advanced Liver Cancer Treatment Landscape. Click here to read more @ Advanced Liver Cancer Pipeline Outlook- https://www.delveinsight.com/sample-request/advanced-cervical-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Advanced Cervical Cancer Pipeline Report
• In April 2025, Amgen announced a study is to evaluate the safety, tolerability, and to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of AMG 193 alone and in combination with docetaxel in adult participants with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-null solid tumors.
• In March 2025, Merck Sharp & Dohme LLC announced a study is to evaluate the efficacy and safety of pembrolizumab plus concurrent chemoradiotherapy compared to placebo plus concurrent chemoradiotherapy in participants with locally advanced cervical cancer.
• In March 2025, AstraZeneca announced a phase III, randomized, double-blind, placebo-controlled, multi-center, global study to explore the efficacy and safety of volrustomig in women with high-risk LACC (FIGO 2018 stage IIIA to IVA cervical cancer) who have not progressed following platinum-based CCRT.
• In January 2025:- Merck Sharp & Dohme LLC:- The purpose of this study is to evaluate the efficacy and safety of pembrolizumab plus concurrent chemoradiotherapy compared to placebo plus concurrent chemoradiotherapy in participants with locally advanced cervical cancer. The primary hypotheses are that pembrolizumab plus concurrent chemoradiotherapy is superior to placebo plus concurrent chemoradiotherapy with respect to progression-free survival and overall survival.
• In January 2025:- AstraZeneca:- A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-centre, Global Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer Who Have Not Progressed Following Platinum-based, Concurrent Chemoradiation Therapy (eVOLVE-Cervical). Women with locally advanced cervical cancer will be randomized in a 1:1 ratio to receive treatment with Volrustomig or Placebo.
• In January 2025:- DualityBio Inc.:- This is a multicenter, open-label, multiple-dose, FIH Phase 1/2a study. Phase 1 adopts the standard "3+3" design to identify: the MTD and/or RP2D of DB-1310 as monotherapy, the RCD_A of DB-1310 in combination with trastuzumab and the RCD_B of DB-1310 in combination with Osimertinib; Phase 2a is a dose expansion phase to confirm the safety, tolerability and explore efficacy in selected malignant solid tumors treated with DB-1310 as monotherapy or in combination with trastuzumab or in combination with Osimertinib.
• In January 2025:- RAPT Therapeutics Inc.:- The study will be conducted in 2 parts, a dose-escalation phase (Part 1) and a cohort expansion phase (Part 2). In Part 1 of the study, subjects will be enrolled in sequential cohorts treated with successively higher doses of FLX475 as monotherapy or in combination with pembrolizumab. In Part 2 of the study, subjects will be initially enrolled in Stage 1 of parallel expansion cohorts of FLX475 as monotherapy or in combination with pembrolizumab.
• In January 2025:- Amgen:- The primary objective of Parts 1 and 2 of this study is to evaluate the safety, tolerability, and to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of AMG 193 alone and in combination with docetaxel in adult participants with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-null solid tumors.
• DelveInsight's Advanced Cervical Cancer pipeline report depicts a robust space with 70+ active players working to develop 75+ pipeline therapies for Advanced Cervical Cancer treatment.
• The leading Advanced Cervical Cancer Companies such as AstraZeneca, GlaxoSmithKline, Advaxis, Bristol-Myers Squibb, Innovent Biologics, Shanghai Henlius Biotech, Biocad, Genexine, Inc., Merck KGaA, Zeria Pharmaceutical, ISA Pharmaceuticals, Agenus Inc., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Vaccibody AS, Fujifilm Pharmaceuticals U.S.A., Inc., NETRIS Pharma,CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Xencor, Inc., Sotio a.s., Andes Biotechnologies, and others.
• Promising Advanced Cervical Cancer Pipeline Therapies such as Durvalumab, Cisplatin, Carboplatin, IBI310, and others.
Stay informed about the cutting-edge advancements in Advanced Cervical Cancer treatments. Download for updates and be a part of the revolution in cancer care @ Advanced Cervical Cancer Clinical Trials Assessment- https://www.delveinsight.com/sample-request/advanced-cervical-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Advanced Cervical Cancer Emerging Drugs Profile
• Imfinzi (durvalumab): AstraZeneca
Imfinzi (durvalumab) is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80 proteins, countering the tumour's immune-evading tactics and releasing the inhibition of immune responses. Imfinzi is the only approved immunotherapy in the curative-intent setting of unresectable, Stage III non-small cell lung cancer (NSCLC) in patients whose disease has not progressed after chemoradiotherapy, and is the global standard of care in this setting based on the PACIFIC Phase III trial. Imfinzi is also approved in the US, EU, Japan, China and many other countries around the world for the treatment of extensive-stage small cell lung cancer based on the CASPIAN Phase III trial. As part of a broad development programme, Imfinzi is being tested as a single treatment and in combinations with other anti-cancer treatments for patients with small cell lung cancer, NSCLC, bladder cancer, several gastrointestinal cancers, ovarian cancer, endometrial cancer and other solid tumours. Currently, it is in Phase III stage of clinical trial evaluation to treat Locally Advanced Cervical Cancer.
• Dostarlimab: GlaxoSmithKline
Dostarlimab is a humanised PD-1 monoclonal antibody that binds with high affinity to the PD-1 receptor and blocks its interaction with the ligands PD-L1 and PD-L2. Currently, it is in Phase II stage of clinical trial evaluation to treat Locally Advanced Cervical Cancer.
• Andes 1537: Andes Biotechnologies
Andes-1537, a proprietary antisense oligonucleotide designed by Andes Biotechnology, is the Company's most advanced investigational drug candidate and the first to enter a human clinical study. It targets a novel non-coding mitochondrial RNA (ncmtRNA) and has demonstrated antineoplastic activity in preclinical studies. Upon administration, Andes-1537 binds to a specific ncmtRNA, inducing cell cycle arrest and apoptosis of cancer cells. Currently the drug is in Phase I stage of Clinical trial evaluation for the treatment of Cervical Cancer.
Learn more about Advanced Cervical Cancer Drugs opportunities in our groundbreaking Advanced Cervical Cancer Research and development projects @ Advanced Cervical Cancer Unmet Needs- https://www.delveinsight.com/sample-request/advanced-cervical-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Advanced Cervical Cancer Companies
AstraZeneca, GlaxoSmithKline, Advaxis, Bristol-Myers Squibb, Innovent Biologics, Shanghai Henlius Biotech, Biocad, Genexine, Inc., Merck KGaA, Zeria Pharmaceutical, ISA Pharmaceuticals, Agenus Inc., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Vaccibody AS, Fujifilm Pharmaceuticals U.S.A., Inc., NETRIS Pharma,CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Xencor, Inc., Sotio a.s., Andes Biotechnologies, and others.
Advanced Cervical Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
Advanced Cervical Cancer Pipeline Products have been categorized under various Molecule types such as-
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
Discover the latest advancements in Advanced Cervical Cancer treatment by visiting our website. Stay informed about how we're transforming the future of oncology @ Advanced Cervical Cancer Market Drivers and Barriers, and Future Perspectives- https://www.delveinsight.com/sample-request/advanced-cervical-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Advanced Cervical Cancer Pipeline Report
• Coverage- Global
• Advanced Cervical Cancer Companies- AstraZeneca, GlaxoSmithKline, Advaxis, Bristol-Myers Squibb, Innovent Biologics, Shanghai Henlius Biotech, Biocad, Genexine, Inc., Merck KGaA, Zeria Pharmaceutical, ISA Pharmaceuticals, Agenus Inc., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Vaccibody AS, Fujifilm Pharmaceuticals U.S.A., Inc., NETRIS Pharma,CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Xencor, Inc., Sotio a.s., Andes Biotechnologies, and others.
• Advanced Cervical Cancer Pipeline Therapies- Durvalumab, Cisplatin, Carboplatin, IBI310, and others.
• Advanced Cervical Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Advanced Cervical Cancer Therapeutics Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Advanced Cervical Cancer Pipeline on our website @ Advanced Cervical Cancer Emerging Drugs and Companies- https://www.delveinsight.com/sample-request/advanced-cervical-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. Advanced Cervical Cancer: Overview
4. Advanced Cervical Cancer Pipeline Therapeutics
5. Advanced Cervical Cancer Therapeutic Assessment
6. Advanced Cervical Cancer - DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment
8. Advanced Cervical Cancer Collaboration Deals
9. Late Stage Products (Phase III)
10. Durvalumab: AstraZeneca
11. Drug profiles in the detailed report.....
12. Mid Stage Products (Phase II)
13. Dostarlimab: GlaxoSmithKline
14. Drug profiles in the detailed report.....
15. Early Stage Products (Phase I)
16. Andes 1537: Andes Biotechnologies
17. Drug profiles in the detailed report.....
18. Inactive Products
19. Advanced Cervical Cancer Key Companies
20. Advanced Cervical Cancer Key Products
21. Advanced Cervical Cancer- Unmet Needs
22. Advanced Cervical Cancer- Market Drivers and Barriers
23. Advanced Cervical Cancer- Future Perspectives and Conclusion
24. Advanced Cervical Cancer Analyst Views
25. Advanced Cervical Cancer Key Companies
26. Appendix
List of Top Selling Market Research Reports in 2025
Myelodysplastic Syndrome With Excess Blasts2 Market- https://www.delveinsight.com/report-store/myelodysplastic-syndrome-market
Neurofibrosarcoma Market- https://www.delveinsight.com/report-store/neurofibrosarcoma-market
Rabies Virus Market- https://www.delveinsight.com/report-store/rabies-infection-market
Liver Angiosarcoma Market- https://www.delveinsight.com/report-store/liver-cancer-market
Eisenmenger Complex Market- https://www.delveinsight.com/sample-request/eisenmenger-complex-market
Medical Marijuana Market- https://www.delveinsight.com/report-store/medical-marijuana-market-insight
Pelvic Inflammatory Disease Market- https://www.delveinsight.com/report-store/chlamydia-market
Neurovascular Catheters Market- https://www.delveinsight.com/report-store/neurovascular-devices-interventional-neurology-market
Uterine Fibroids Treatment Devices Market- https://www.delveinsight.com/report-store/endometrial-ablation-devices-market
Tadekinig Alfa Market- https://www.delveinsight.com/sample-request/tadekinig-alfa-emerging-insight-and-market-forecast
Dermatomycoses Market- https://www.delveinsight.com/report-store/dermatomyositis-market
Menopause Market- https://www.delveinsight.com/report-store/menopause-market-forecast
Muscle Atrophy/ Wasting Syndrome Market- https://www.delveinsight.com/report-store/sarcopenia-market
Pleural Diseases Market - https://www.delveinsight.com/report-store/malignant-pleural-effusion-market
Orthopedic Splints Device Market- https://www.delveinsight.com/report-store/orthotic-devices-market
Inflammatory Bowel Disease Market- https://www.delveinsight.com/report-store/inflammatory-bowel-disease-market
Liquid Biospy For Cancer Diagnostics Market- https://www.delveinsight.com/report-store/liquid-biopsy-in-cancer-diagnostics-market
Vascular Graft Devices Market- https://www.delveinsight.com/report-store/vascular-grafts-market
Blood Glucose Monitoring Systems Market- https://www.delveinsight.com/report-store/blood-glucose-monitoring-systems-market
Breast Pumps Market- https://www.delveinsight.com/report-store/breast-pumps-market
Obesity Market- https://www.delveinsight.com/report-store/weight-loss-weight-management-obesity-market
Adalimumab Biosimilar- https://www.delveinsight.com/report-store/adalimumab-biosimilars-insight
ADHD Market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
Adamantinoma Market- https://www.delveinsight.com/sample-request/adamantinoma-market
Cataract Market- https://www.delveinsight.com/report-store/cataract-surgery-devices-market
Mitochondrial Myopathies Market- https://www.delveinsight.com/report-store/mitochondrial-myopathies-market
Optic Atropy Market- https://www.delveinsight.com/report-store/autosomal-dominant-optic-atrophy-market
Transfusion-dependent Thalassaemia Market- https://www.delveinsight.com/report-store/transfusion-dependent-thalassaemia-market
Acute Pain Market- https://www.delveinsight.com/report-store/acute-pain-market
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Advanced Cervical Cancer Pipeline Appears Robust With 70+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight here
News-ID: 4059350 • Views: …
More Releases from DelveInsight Business Research LLP
Germ Cell Tumors Market: Epidemiology, Therapies, Companies, DelveInsight | Take …
Germ Cell Tumors emerging therapies such as Cabozantinib, are expected to boost the Germ Cell Tumors Market in the upcoming years.
DelveInsight has launched a new report on "Germ Cell Tumors - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Germ Cell Tumors, historical and forecasted epidemiology as well as the Germ Cell Tumors market trends in the United States, EU5 (Germany, Spain, Italy, France, and…
Giant Cell Arteritis Pipeline 2025: Groundbreaking Clinical Advancements by 80+ …
With Giant Cell Arteritis reaching epidemic proportions globally and contributing significantly to comorbid conditions such as diabetes, cardiovascular disease, and certain cancers, there is a growing demand for safer, more effective treatment options. According to DelveInsight, the Giant Cell Arteritis pipeline comprises 6+ pharmaceutical and biotech companies actively developing 6+ therapeutic candidates targeting Giant Cell Arteritis. These therapies span various stages of clinical and non-clinical development, underscoring the intense innovation…
Pheochromocytoma Pipeline 2025: Groundbreaking Clinical Advancements by 3+ Globa …
With Pheochromocytoma reaching epidemic proportions globally and contributing significantly to comorbid conditions such as diabetes, cardiovascular disease, and certain cancers, there is a growing demand for safer, more effective treatment options. According to DelveInsight, the Pheochromocytoma pipeline comprises 3+ pharmaceutical and biotech companies actively developing 3+ therapeutic candidates targeting Pheochromocytoma. These therapies span various stages of clinical and non-clinical development, underscoring the intense innovation and commitment to addressing one of…
Presbyopia Pipeline 2025: Groundbreaking Clinical Advancements by 10+ Global Lea …
With Presbyopia reaching epidemic proportions globally and contributing significantly to comorbid conditions such as diabetes, cardiovascular disease, and certain cancers, there is a growing demand for safer, more effective treatment options. According to DelveInsight, the Presbyopia pipeline comprises 10+ pharmaceutical and biotech companies actively developing 10+ therapeutic candidates targeting Presbyopia. These therapies span various stages of clinical and non-clinical development, underscoring the intense innovation and commitment to addressing one of…
More Releases for Cancer
Cancer Therapeutics Market New Business Opportunities to Hit $180.19 billion by …
Surge in geriatric population and rise in the number of collaborations & partnerships to facilitate drug development are the key drivers of the global cancer therapeutics market. In addition, heavy inflow of investment in R&D activities has enhanced the development of cancer therapeutics. Furthermore, favorable government regulations for cancer therapeutics and surge in cancer prevalence boost the market. The high demand for personalized medicine along with high potential of emerging…
Global Cancer Diagnostics Market Size, Trends & Growth Opportunity By Applicatio …
Cancer diagnostics is a process of detecting various proteins, biomarkers and certain symptoms that result in the detection of presence of cancerous tumour in patients. Detection of certain proteins and biomarkers which are prevalent in cancer disorder thereby results in diagnosis process. Cancer diagnostics includes usage of certain technology and devices for detection purpose.
Increase in incidence of target diseases like cancer is key driving factor which is expected to boost…
Oncology Nutrition Market led to an unprecedented rise by 2025 : liver cancer, p …
Global Oncology Nutrition Market: Overview
Cancer diagnosis creates myriad questions about diet and nutrition. Those pertain to if the food will make a patient feel sick to what should be ingested to fight cancer. This has spawned the oncology nutrition market which has been rising steadily due to the increasing cases of different types of cancer worldwide. During cancer treatment one needs to eat right in order to build up strength…
Cancer Immunotherapy Market 2018 To 2025 - SWOT Analysis By Global Industry Reve …
The Cancer Immunotherapy Market research report provided by Crystal Market Research (CMR) is the most detailed study about Cancer Immunotherapy Market that is estimated to grow at a tremendous rate over the forecast period 2018-2025. This report contains precise and updated insights in respect with the leading market players and prevailing regions of the business.
Cancer Immunotherapy Market By Product and Cancer Type - Global Industry Analysis And Forecast To 2025:…
Oncology Nutrition Market by Cancer Type Breast Cancer, Liver Cancer, Lung Cance …
Lunch of new products for nutrition of oncology patients is expected to drive the oncology nutrition market growth. For instance, in 2016, Hormel Food Corporation, a U.S-based meat food products company, launched a line of packaged ready-to-eat meals for cancer patients, which are called as Hormel Vital Cuisine.
These meals consist of carbohydrates, proteins, and fats to help patients fight loss of muscle mass and energy during cancer treatment. Thus launch…
Cancer Diagnostics Global Market: By Application - Breast Cancer, Lung Cancer, C …
Researchmoz added Most up-to-date research on "Cancer Diagnostics Global Market: By Application - Breast Cancer, Lung Cancer, Colorectal Cancer, Melanoma & Other Cancers" to its huge collection of research reports.
This report studies Cancer Diagnostics in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022.
This report focuses on top…
